10:20:03 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-09-19 Kvartalsrapport 2024-Q2
2024-06-07 Årsstämma 2024
2024-04-18 Bokslutskommuniké 2023
2023-09-28 Kvartalsrapport 2023-Q2
2023-06-12 Ordinarie utdelning EXTX 0.00 NOK
2023-06-09 Årsstämma 2023
2023-04-21 Bokslutskommuniké 2022
2022-09-22 Kvartalsrapport 2022-Q2
2022-06-09 Ordinarie utdelning EXTX 0.00 NOK
2022-06-08 Årsstämma 2022
2022-04-27 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriBioteknik
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.
2023-09-26 08:30:00
OSLO, September 26, 2023: EXACT THERAPEUTICS AS ("EXACT-Tx", Euronext Growth:
EXTX), a clinical stage precision health company utilising Acoustic Cluster
Therapy (ACT®) across multiple therapeutic areas, today announces positive
safety and anticancer activity results from the dose escalation part of the
ACTIVATE trial. The data will be presented at a medical conference in early
2024.

"We are encouraged by these results from the dose escalation part of the trial.
The results indicate that ACT treatment is tolerable and enhances the anticancer
effect of chemotherapy in this hard-to-treat patient population. These results
support the translation of our pre-clinical data and add confidence for further
clinical development" says Dr Amir Snapir, CMO of EXACT Therapeutics.

Eight patients were enrolled into the dose escalation part of the study. The
results suggest that ACT treatment in combination with FOLFOX or FOLFIRI is well
tolerated without unexpected acute or delayed side effects of the ACT treatment
or worsening of side effects of the chemotherapy. Positive anticancer responses
have been seen in all but one of the evaluable patients in this hard-to-treat
patient population, showing that the ACT treatment can enhance anticancer
response to Standard of Care chemotherapy.

For more information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

About ACTIVATE:
The ACTIVATE study ("PS101-mediated ACT with Chemotherapy in Liver Metastases
From Cancer of Gastrointestinal Origin, NCT04021277") is a two-part Phase I dose
escalation and dose finding study of PS101-mediated ACT combined with standard
of care chemotherapy for the treatment of liver metastasis in patients with
advanced solid tumours, with an expansion part in colorectal cancer (CRC) and
pancreatic duct adenocarcinoma (PDAC) patients.

About EXACT-Tx:
EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to significantly amplify the clinical
utility of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy) and brain diseases.
www.exact-tx.com

About ACT®
o ACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.
o ACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
o Initial focus of the Company is oncology, however the ACT® platform has
potential across therapeutic areas (CNS, immunotherapy) and product classes.

Forward looking statements: This announcement and any materials distributed in
connection with this announcement may contain certain forward-looking
statements. By their nature, forward-looking statements involve risk and
uncertainty because they reflect the Company's current expectations and
assumptions as to future events and circumstances that may not prove accurate. A
number of material factors could cause actual results and developments to differ
materially from those expressed or implied by this forward-looking statement.